4597 Solasia Pharma K.K. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4597

TSE Growth

Solasia Pharma K.K.

JPY

-1

(-2.94%)

Dec 5, 3:30 pm JST

0.21

USD

Dec 5, 1:30 am EST

Result

PTS

outside of trading hours

32.6

Dec 5, 11:54 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2021	559	-2,419	-2,442	-2,478	-19.0	0	Feb 9, 2022	IFRS
Dec, 2022	1,092	-2,470	-2,492	-2,548	-16.8	0	Feb 14, 2023	IFRS
Dec, 2023	617	-1,139	-1,135	-1,112	-6.6	0	Feb 14, 2024	IFRS
Dec, 2024	316	-1,951	-1,961	-1,941	-9.8	0	Feb 12, 2025	IFRS
Dec, 2025 Guidance	1,300	-650	-650	-650	-2.5	0	Feb 12, 2025	IFRS
YoY	+311.4%	+66.7%	+66.9%	+66.5%	+74.4%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2020	Feb 13, 2020	1,250	-2,450	-2,450	-2,450	0	IFRS
	Dec 15, 2020	450	-4,200	-4,200	-4,200	0	IFRS
Results	Feb 10, 2021	454	-4,116	-4,159	-4,127	0	IFRS
Dec, 2021	Feb 10, 2021	Available in future release
	Nov 10, 2021
Results	Feb 9, 2022
Dec, 2022	Feb 9, 2022
	Nov 14, 2022
	Nov 25, 2022
Results	Feb 14, 2023
Dec, 2023	Feb 14, 2023
	Dec 28, 2023
Results	Feb 14, 2024
Dec, 2024	Feb 14, 2024
	May 15, 2024
	Dec 27, 2024
	Jan 6, 2025
Results	Feb 12, 2025
Dec, 2025	Feb 12, 2025	1,300	-650	-650	-650	0	IFRS

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 2011	0	－	Available in future release
Dec, 2012	0	－
Dec, 2013	10	－
Dec, 2014	11	+10.0
Dec, 2015	229	+1,981.8
Dec, 2016	501	+118.8
Dec, 2017	410	-18.2
Dec, 2018	318	-22.4
Dec, 2019	1,310	+311.9
Dec, 2020	454	-65.3
Dec, 2021	559	+23.1
Dec, 2022	1,092	+95.3
Dec, 2023	617	-43.5
Dec, 2024	316	-48.8
Dec, 2025 Guidance	1,300	+311.4	-650	+66.7	-650	+66.9	-2.5	+74.5

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2023	617	-1,139	-185	-49.02	-41.47	0.23	-6.6
Dec, 2024	316	-1,951	-617	-128.08	-108.10	0.18	-9.8
Dec, 2025 Guidance	1,300	-650	-50	-36.19	-27.78	0.56	-2.5

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	1,310	-462	-494	-474	-6.6
Fiscal Year	Dec, 2019	Dec, 2016	Dec, 2016	Dec, 2016	Dec, 2023

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2022	903	-1,242	-1,259	-1,301	-8.6	0	Feb 14, 2023	IFRS
Jul - Dec, 2023	88	-677	-685	-675	-4.0	0	Feb 14, 2024	IFRS
Jul - Dec, 2024	244	-1,340	-1,334	-1,330	-6.7	0	Feb 12, 2025	IFRS
Jul - Dec, 2025 Guidance	1,251	-113	-95	-95	-0.4	0	Aug 13, 2025	IFRS
YoY	+412.7%	+91.6%	+92.9%	+92.9%	+94.5%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2022	-2,470	-2,492	-2,074	-418	2,571	803	25.62	IFRS
Dec, 2023	-1,139	-359	-359	0	275	728	32.66	IFRS
Dec, 2024	-1,951	-1,033	-1,033	0	1,180	886	65.05	IFRS

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2023	602	-787	-784	-768	-4.6	ー	Nov 13, 2023	IFRS
Jan - Sep, 2024	81	-892	-892	-871	-4.5	ー	Nov 13, 2024	IFRS
Jan - Sep, 2025	91	-713	-725	-726	-3.2	ー	Nov 14, 2025	IFRS
YoY	+12.3%	+20.1%	+18.7%	+16.6%	+30.2%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	15	-352	-351	-344	-2.1	-2,346.7	Feb 14, 2024	IFRS
Jan - Mar, 2024	11	-307	-318	-310	-1.8	-2,790.9	May 15, 2024	IFRS
Apr - Jun, 2024	61	-304	-309	-301	-1.7	-498.4	Aug 14, 2024	IFRS
Jul - Sep, 2024	9	-281	-265	-260	-1.4	-3,122.2	Nov 13, 2024	IFRS
Oct - Dec, 2024	235	-1,059	-1,069	-1,070	-5.4	-450.6	Feb 12, 2025	IFRS
Jan - Mar, 2025	25	-296	-292	-292	-1.3	-1,184.0	May 14, 2025	IFRS
Apr - Jun, 2025	24	-241	-263	-263	-1.2	-1,004.2	Aug 13, 2025	IFRS
Jul - Sep, 2025	42	-176	-170	-171	-0.7	-419.0	Nov 14, 2025	IFRS
YoY	+366.7%	+37.4%	+35.8%	+34.2%	+45.2%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	167	-83.6	Available in future release
Jan - Mar, 2021	91	-41.7
Apr - Jun, 2021	187	+122.6
Jul - Sep, 2021	5	-89.4
Oct - Dec, 2021	276	+65.3
Jan - Mar, 2022	113	+24.2
Apr - Jun, 2022	76	-59.4
Jul - Sep, 2022	296	+5,820.0
Oct - Dec, 2022	607	+119.9
Jan - Mar, 2023	220	+94.7
Apr - Jun, 2023	309	+306.6
Jul - Sep, 2023	73	-75.3
Oct - Dec, 2023	15	-97.5
Jan - Mar, 2024	11	-95.0
Apr - Jun, 2024	61	-80.3
Jul - Sep, 2024	9	-87.7
Oct - Dec, 2024	235	+1,466.7
Jan - Mar, 2025	25	+127.3
Apr - Jun, 2025	24	-60.7
Jul - Sep, 2025	42	+366.7	-176	+37.4	-170	+35.8	-0.7	+50.0

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	1,019	129	128	134	1.7
Fiscal Year	Dec, 2019	Sep, 2017	Sep, 2017	Sep, 2017	Sep, 2017

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2022	15.85	84.9	3,134	2,662	-223	0.01	Feb 14, 2023	IFRS
Dec, 2023	10.78	84.1	2,229	1,875	-1,336	0.03	Feb 14, 2024	IFRS
Dec, 2024	5.30	84.9	1,362	1,156	-3,277	0.02	Feb 12, 2025	IFRS
Jan - Sep, 2025	6.92	76.8	2,340	1,796	-370	0.06	Nov 14, 2025	IFRS

Solasia Pharma K.K.(4597) Financial Results